Cargando…
The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer
Human trophoblastic cell surface antigen 2 (Trop2) has been reported to act oncogenically. In this study, one-step quantitative real-time polymerase chain reaction (qPCR) test and immunohistochemistry (IHC) analysis with were employed to evaluate the relationship between Trop2 expression and the cli...
Autores principales: | Mao, Yuan, Wang, Xiaoying, Zheng, Feng, Wang, Changjun, Tang, Qi, Tang, Xiaojun, Xu, Ning, Zhang, Huiling, Zhang, Dawei, Xiong, Lin, Liang, Jie, Zhu, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029744/ https://www.ncbi.nlm.nih.gov/pubmed/27050150 http://dx.doi.org/10.18632/oncotarget.8529 |
Ejemplares similares
-
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
por: Xu, Caili, et al.
Publicado: (2023) -
A Human Anti-c-Met Fab Fragment Conjugated with Doxorubicin as Targeted Chemotherapy for Hepatocellular Carcinoma
por: Chen, Ximin, et al.
Publicado: (2013) -
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022) -
Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab
por: Huang, Jianfei, et al.
Publicado: (2015) -
Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts.
por: Otsuji, E., et al.
Publicado: (1996)